GOLDEN, Colo. — December 10, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced the publication in NPJ Vaccines of the US Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 clinical trial to evaluate the
View GOLDEN, Colo. — November 12, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 13, 2024 at the International mRNA Health Conference 2024. The PharmaJet poster (#32), entitled Modulating Immune Responses
View 
GOLDEN, Colo. — November 5, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 8, 2024 at the Society of Immunotherapy of Cancer (SITC) conference. The poster (#741), entitled Modulating Immune
View 
GOLDEN, Colo. — October 24, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced the results of an implementation study in Nigeria that evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine
View GOLDEN, Colo. — October 17, 2024 — PharmaJet® , a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share their latest research results at the World Vaccine Congress – Europe on October 29, 2024 at 1:40 pm GMT.
View GOLDEN, Colo. — October 2, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that Wouter Latour, M.D., has joined the company as Chief Executive Officer (CEO). Latour also joins the PharmaJet board of directors. He succeeds Chris
View GOLDEN, Colo. — September 17, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that it has entered into a long-term license and supply agreement with Scancell Holdings plc (LSE – SCLP.L) to use the US FDA 510(k)-cleared
View GOLDEN, Colo. — June 27, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its innovative delivery systems, today announced that their Tropis® Intradermal (ID) Needle-free System will be used in a house-to-house polio immunization campaign. With an aim of significantly reducing the
View 
GOLDEN, Colo. — April 24, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of medicines with its innovative delivery systems, today announced the Nature publication of Gennova Biopharmaceutical’s Phase 2/3 clinical trial conducted to evaluate the safety and immunogenicity of its novel samRNA-based Covid-19 vaccine
View Load more